Pancreatic Cancer Research

ResearcherCity of HopeActive in the last 2 years

Kelly J. Lafaro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7070-7269; OpenAlex author ID A5025923620. Sources: OpenAlex.

Their work

Papers
38 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
165
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 9 papers · 2023: 4 papers · 2024: 6 papers · 2025: 7 papers · 2026: 6 papers

Papers 38

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  4. Integrated driver gene-based survival prediction in resected pancreatic cancer. Co-author DOI 10.1093/bjs/znag123↗
  5. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  6. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  7. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  8. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  9. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  10. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  11. The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Co-author DOI 10.1097/sla.0000000000006823↗
  12. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  13. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  14. Sociodemographic variation in the utilization of minimally invasive surgical approaches for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2024.07.403↗
  15. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  16. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  17. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  18. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  19. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  20. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  21. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  22. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  23. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  24. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  25. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mco2.184↗
  26. Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Co-author DOI 10.1007/s00261-021-03353-9↗
  27. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  28. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  29. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Last author DOI 10.1067/j.cpradiol.2022.05.001↗
  30. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  31. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  32. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an In… Co-author DOI 10.1245/s10434-021-11081-z↗
  33. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗
  34. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.jamcollsurg.2020.11.018↗
  35. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". Co-author DOI 10.1016/j.surg.2020.08.031↗
  36. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… Co-author DOI 10.1245/s10434-020-09201-2↗
  37. Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.07.054↗
  38. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Co-author DOI 10.1016/j.ajpath.2018.09.009↗

Closest collaborators

The 25 strongest of 165 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 29 shared papers, 2020–2026 · strength 4.56
  2. Richard Andrew Burkhart · 26 shared papers, 2020–2026 · strength 4.19
  3. Ammar A. Javed · 23 shared papers, 2020–2026 · strength 3.49
  4. Joseph R. Habib · 22 shared papers, 2020–2026 · strength 3.37
  5. William R. Burns · 20 shared papers, 2020–2025 · strength 2.82
  6. Christopher R. Shubert · 14 shared papers, 2022–2026 · strength 2.58
  7. Christopher Lee Wolfgang · 16 shared papers, 2020–2026 · strength 2.30
  8. Benedict Kinny‐Köster · 14 shared papers, 2020–2025 · strength 1.95
  9. Brady A. Campbell · 9 shared papers, 2024–2026 · strength 1.81
  10. William Reece Burns · 7 shared papers, 2025–2026 · strength 1.54
  11. Christopher L. Wolfgang · 10 shared papers, 2022–2025 · strength 1.53
  12. Paul C. M. Andel · 8 shared papers, 2024–2026 · strength 1.44
  13. Lei Zheng · 9 shared papers, 2022–2026 · strength 1.39
  14. Lois A. Daamen · 8 shared papers, 2024–2026 · strength 1.38
  15. Izaak Quintus Molenaar · 8 shared papers, 2024–2026 · strength 1.38
  16. Ingmar Florin Rompen · 7 shared papers, 2024–2026 · strength 1.19
  17. Ding Ding · 8 shared papers, 2021–2026 · strength 1.17
  18. Marc G. Besselink · 7 shared papers, 2024–2026 · strength 1.15
  19. Ralph H. Hruban MD · 7 shared papers, 2021–2026 · strength 1.11
  20. Elizabeth M. Jaffee · 5 shared papers, 2022–2026 · strength 0.99
  21. Sami Shoucair · 7 shared papers, 2021–2023 · strength 0.97
  22. Greg D. Sacks · 5 shared papers, 2024–2025 · strength 0.89
  23. Amol Kumar Narang · 6 shared papers, 2022–2026 · strength 0.87
  24. Jun Yu · 6 shared papers, 2021–2023 · strength 0.84
  25. Richard A. Burkhart · 4 shared papers, 2021–2026 · strength 0.80

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.